Randomized trial demonstrates superior detection of gallbladder carcinoma using 68 Ga-FAPI PET/CT, indicating improved early diagnostic capabilities.
Gallbladder carcinoma contributes 50% of biliary tract cancers. Its gradual onset and nonspecific early symptoms often delay diagnosis, making early detection and treatment vital for better outcomes. 68 Ga-labelled fibroblast activation protein inhibitor (FAPI), an emerging positron emission tomography (PET) tracer, has demonstrated its diagnostic superiority over 18 F-fluorodeoxyglucose PET/computed tomography ( 18 F-FDG PET/CT) in the detection of primary and metastatic lesions across various malignancies. Here, our case represents the superiority of 68 Ga FAPI PET/CT over the 18 F-FDG PET/CT scan in the detection of the carcinoma gallbladder.
No takes yet. Share an insight, caveat, or question.
Pal et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: